Precision Medicine in Psychiatric Drug Development

Time: 12:25 pm
day: Day Two


• Important challenges for novel drug development include patient heterogeneity and lack of established biomarkers to help with patient selection
• Genetic information may help, but it will not be enough. The field needs to seek and validate multimodal biomarker approaches
• Biomarkers that capture functional state of relevant neural circuits will be important to test. A significant amount of investigation is taking place in this area.
• We need to think of patient subsets that are ideal for the mechanism of action of novel treatments, and this should rely on domain-related multimodal biomarkers as well as disease staging.